In order for these therapies to work most effectively, you need first to determine if your tumor tissue is positive for the BRAF mutation.  As demonstrated in laboratory studies, the most common alteration in the BRAF gene leads to the V600E mutation and that is what the testing will seek to determine.  Currently, testing takes place at most university based pathology labs or through the clinical trial pre-testing program but there may soon be an approved test for those centers without the testing available.